|Bid||57.00 x 100000|
|Ask||57.50 x 100000|
|Day's Range||56.50 - 57.50|
|52 Week Range||42.20 - 61.00|
|Beta (5Y Monthly)||0.41|
|PE Ratio (TTM)||22.95|
|Forward Dividend & Yield||1.45 (2.54%)|
|Ex-Dividend Date||Mar 27, 2020|
|1y Target Est||N/A|
People with diabetes using Novo Nordisk Inc. insulin who have lost health insurance coverage because of a change in job status due to the COVID-19 pandemic may now be eligible for enrollment in our Diabetes Patient Assistance Program (PAP) and receive insulin free of charge for 90 days.
We recognize that people with chronic diseases, including diabetes, obesity and hemophilia, are at increased risk during this pandemic and Novo Nordisk is taking measures to support the communities we serve throughout the COVID-19 pandemic.
Today, Novo Nordisk launched the My$99Insulin Program, follow-on brands of insulins, and an Immediate Supply option, expanding its insulin affordability offering to help people with diabetes who need alternative solutions. These options, along with information on the existing patient assistance program, copay cards, and where to find $25/vial human insulin, are now available online at NovoCare.com or by calling 1.844.NOVO4ME (1.844.668.6463).